PTC Therapeutics Reports Positive Huntington’s Disease Trial Results

PTC Therapeutics (NASDAQ:PTCT) announced positive interim results from its PIVOT-HD extension trial for votoplam in treating Stage 2 Huntington's disease. Patients on the higher dose showed a significant slowdown in disease progression, potentially boosting investor confidence.

By Sheryar Siddiq May 2, 2026 1 min read · Yahoo Finance · May 2, 2026, 17:51 UTC

PTC Therapeutics Reports Positive Huntington’s Disease Trial Results

Tickers: $PTCT

Topics: biotech Huntington's disease votoplam

Read the full article at Yahoo Finance

More World news

Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC